Rituximab for chronic lymphocytic leukemia

Bibliography

• Keating GM. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 2010;70:1445-76
   PubMed Web of Science ®Google Scholar
• Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005;8:140-74
   PubMedGoogle Scholar
• Beers SA, Chan CH, French RR, CD20 as a target for therapeutic type 1 and 2 monoclonal antibodies. Semin Hematol 2010;47:107-14
   PubMed Web of Science ®Google Scholar
• Li H, Ayer LM, Lytton J, Deans JP. Store-operated cation entry mediated by CD20 in membrane rafts. J Biol Chem 2003;278:42427-34
   PubMed Web of Science ®Google Scholar
• Reff ME, Carner K, Chambers KS, Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45
   PubMed Web of Science ®Google Scholar
• Maloney DG. Mechanism of action of rituximab. Anticancer Drugs 2001;12(Suppl 2):1-4
   PubMed Web of Science ®Google Scholar
• Zhou X, Hu W, Qin X. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist 2008;13:954-66
   PubMed Web of Science ®Google Scholar
• Golay J, Zaffaroni L, Vaccari T, Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement mediated cell lysis. Blood 2000;95:3900-8
   PubMed Web of Science ®Google Scholar
• Cragg MS, Morgan SM, Chan HT, Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003;101:1045-52
   PubMed Web of Science ®Google Scholar
• Manches O, Lui G, Chapero L, In vitro mechanism of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003;101:949-54
   PubMed Web of Science ®Google Scholar
• Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal tibodies. Blood 1998;91:1644-52
   PubMed Web of Science ®Google Scholar
• Onrust SV, Lamb HM, Balfour JA. Rituximab. Drugs 1999;58:79-88
   PubMed Web of Science ®Google Scholar
• Byrd JC, Kitada S, Flinn IW, The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002;99:1038-43
   PubMed Web of Science ®Google Scholar
• Zhou X, Hu W, Qin X. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist 2008;13:954-66
   PubMed Web of Science ®Google Scholar
• Suzuki E, Umezawa K, Bonavida B. Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis. Oncogene 2007;26:6184-9
   PubMed Web of Science ®Google Scholar
• Chow KU, Sommerlad WD, Boehrer S, Anti-CD20 antibody (IDEC- C238, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement and caspases. Haematologica 2002;87:33-43
   PubMed Web of Science ®Google Scholar
• Redaelli A, Laskin BL, Stephens JM, The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur J Cancer Care 2004;13:279-87
   Web of Science ®Google Scholar
• CLL Trialists Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J NatlCancer Inst 1999;91:861-8
   PubMed Web of Science ®Google Scholar
• Robak T, Kasznicki M. Alkylating agents and nucleoside analogues in the treatment of B-cell chronic lymphocytic leukemia. Leukemia 2002;16:1015-27
   PubMed Web of Science ®Google Scholar
• Rai KR, Peterson BL, Appelbaum FR, Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750-7
   PubMed Web of Science ®Google Scholar
• Robak T, Blonski JZ, Kasznicki M, Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000;96:2723-9
   PubMed Web of Science ®Google Scholar
• Eichhorst BF, Busch R, Hopfinger G, Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006;107:885-91
   PubMed Web of Science ®Google Scholar
• Robak T, Jamroziak K, Gora-Tybor J, Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a Phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J Clin Oncol 2010;28:1861-9
   Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase III trial. Lancet 2010;376:1164-74
   PubMed Web of Science ®Google Scholar
• Robak T, Dmoszynska A, Solal-Celigny A, Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previouslytreated chronic lymphocytic leukemia. J Clin Oncol 2010;28:1756-65
   PubMed Web of Science ®Google Scholar
• Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 2001;7:709-23
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Litchy S, Barton JH, Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a Phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003;21:1746-51
   PubMed Web of Science ®Google Scholar
• Huhn D, von Schilling C, Wilhelm M, Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001;98:1326-31
   PubMed Web of Science ®Google Scholar
• Nguyen DT, Amess JA, Doughty H, IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur J Haematol 1999;62:76-82
   PubMed Web of Science ®Google Scholar
• Schulz H, Klein SK, Rehwald U, Phase II study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2002;100:3115-20
   PubMed Web of Science ®Google Scholar
• Del Poeta G, DelPrincipe MI, Consalvo MA, The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70 negative chronic lymphocytic leukemia. Cancer 2005;104:2743-52
   PubMed Web of Science ®Google Scholar
• Byrd JC, Peterson BL, Morrison VA, Randomized phase II study of fludarabine with concurrent vs sequential treatment with rituximab in symptomatic untreated patients with B-cell chronic lymphocytic leukemia results from Cancer and Leukemia Group B 9712 (CALG B9712). Blood 2003;101:6-14
   PubMed Web of Science ®Google Scholar
• Byrd J, Rai K, Peterson BL, Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:49-53
   PubMed Web of Science ®Google Scholar
• Woyach JA, Ruppert AS, Heerema NA, Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol 2011;29:1349-55
   PubMed Web of Science ®Google Scholar
• Keating MJ, O'Brien S, Albitar M, Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079-88
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Tam C, Abruzzo LV, Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer 2009;115:373-80
   PubMed Web of Science ®Google Scholar
• Foon KA, Boyiadzis M, Land SR, Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:498-503
   PubMed Web of Science ®Google Scholar
• Robak T. How to improve the treatment outcome in chronic lymphocytic leukemia? Leuk Res 2010;34:272-5
   PubMed Web of Science ®Google Scholar
• Faderl S, Wierda W, O'Brien S, Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL < 70 Years. Leuk Res 2010;34:2842-8
   Google Scholar
• Bosch F, Abrisqueta P, Villamor N, Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active hemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol 2009;27:4578-84
   PubMed Web of Science ®Google Scholar
• Bosch F, Abrisque P, Villamor N, Rituximab maintenance in patients with chronic lymphocytic leukemia (CLL) after upfront treatment with rituximab plus fludarabine, cyclophosphamide, and mitoxantrone (R-FCM): final results of a multicenter phase II trial on behalf of the Spanish CLL Study Group (GELLC) [abstract 293]. Blood 2011;118:136
   Web of Science ®Google Scholar
• Parikh SA, Keating MJ, O'Brien S, Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood 2011;118:2062-8
   PubMed Web of Science ®Google Scholar
• Kay NE, Geyer SM, Call TG, Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007;109:405-11
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Lin T, Geyer SM, Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer 2007;109:2291-8
   PubMed Web of Science ®Google Scholar
• Reynolds C, Di Bella N, Lyons RM, A phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. Invest New Drugs [Epub ahead of print, 16 September 2011; doi: 10.1007/s10637-011-9737-y]
   Web of Science ®Google Scholar
• Castro JE, James DF, Sandoval-Sus JD, Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia 2009;23:1779-89
   PubMed Web of Science ®Google Scholar
• Fischer K, Cramer P, Stilgenbauer S, Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: a multicenter phase II trial of the German CLL Study Group(GCLLSG) [abstract 205]. Blood 2009;114:89
   Web of Science ®Google Scholar
• German CLL Study Group, National Cancer Institute (NCI). Fludarabine, Cyclophosphamide, and Rituximab or Bendamustine and Rituximab in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia ClinicalTrials.gov NCT00769522. Available from: http://clinicaltrials.gov/ct2/results?term=NCT00769522
   Google Scholar
• Herold M, Schulze A, Hartwig K, Anger G. Successful treatment and re-treatment of resistant B-cell chronic lymphocytic leukemia with the monoclonal anti-CD20 antibody rituximab. Ann Hematol 2000;79:332-5
   PubMed Web of Science ®Google Scholar
• Itala M, Geisler CH, Kimby E, Standard dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. Eur J Haematol 2002;69:129-34
   PubMed Web of Science ®Google Scholar
• O'Brien SM, Kantarjian H, Thomas DA, Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19:2165-70
   PubMed Web of Science ®Google Scholar
• Byrd JC, Murphy T, Howard RS, Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001;19:2153-64
   PubMed Web of Science ®Google Scholar
• Wiernik PH, Adiga GU. Single-agent rituximab in treatment-refractory or poor prognosis patients with chronic lymphocytic leukemia. Curr Med Res Opin 2011;27:1987-93
   PubMed Web of Science ®Google Scholar
• Robak T, Lech-Maranda E, Robak P. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia. Expert Rev Anticancer Ther 2010;10:1529-43
   PubMed Web of Science ®Google Scholar
• Wierda W, O'Brien S, Wen S, Chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005;23:4070-8
   PubMed Web of Science ®Google Scholar
• Dornan D, Spleiss O, Yeh RF, Effect of FCGR2A and FCGR3A variants on CLL outcome. Blood 2010;116:4212-22
   PubMed Web of Science ®Google Scholar
• Wierda WG, O'Brien SM, Faderl SH, Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active regimen for heavily treated patients with CLL [abstract 31]. Blood 2006;108:14a
   Web of Science ®Google Scholar
• Hillmen P, Cohen DR, Cocks K, A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia. Br J Haematol 2011;152:570-8
   PubMed Web of Science ®Google Scholar
• Byrd JC, Kipps TJ, Flinn IW, Phase I/II study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2010;115:489-95
   PubMed Web of Science ®Google Scholar
• Biogen Idec. Lumiliximab With Fludarabine, Cyclophosphamide, and rituximab (FCR) versus fcr alone in subjects with relapsed chronic lymphocytic leukemia (CLL) (LUCID). ClinicalTrials.gov NCT00391066. Available from: http://clinicaltrials.gov/ct2/results?term=NCT00391066
   Google Scholar
• Lamanna N, Kalaycio M, Maslak P, Pentostatin, cyclophosphamide and rituximab is an active well tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2006;24:1575-81
   PubMed Web of Science ®Google Scholar
• Robak T, Smolewski P, Cebula B, Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Cancer 2006;107:1542-50
   PubMed Web of Science ®Google Scholar
• Robak T, Smolewski P, Cebula B, Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia. Eur J Haematol 2007;79:107-13
   PubMed Web of Science ®Google Scholar
• Fischer K, Cramer P, Busch R, Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011;29:3559-66
   PubMed Web of Science ®Google Scholar
• Nabhan C, Patton D, Gordon LI, A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma 2004;45:2269-73
   PubMed Web of Science ®Google Scholar
• Faderl S, Ferrajoli A, Wierda W, Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence. Cancer 2010;116:2360-5
   PubMed Web of Science ®Google Scholar
• Castro JE, Sandoval-Sus JD, Bole J, Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 2008;22:2048-53
   PubMed Web of Science ®Google Scholar
• Bowen DA, Call TG, Jenkins GD, Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma 2007;48:2412-17
   PubMed Web of Science ®Google Scholar
• Salles G, Seymour JF, Offner F, Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase III, randomised controlled trial. Lancet 2010;377:42-51
   PubMed Web of Science ®Google Scholar
• O'Brien S, Kay NE. Maintenance therapy for B-chronic lymphocytic leukemia. Clin Adv Hematol Oncol 2011;9:22-3
   PubMedGoogle Scholar
• Keating GM. Spotlight on rituximab in chronic lymphocytic leukemia, low-grade or follicular lymphoma, and diffuse large B-cell lymphoma. BioDrugs 2011;25:55-61
   PubMed Web of Science ®Google Scholar
• Del Poeta G, Del Principe MI, Buccisano F, Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Cancer 2008;112:119-28
   PubMed Web of Science ®Google Scholar
• Srock S, Schriever F, Neubauer A, Long-term treatment with rituximab is feasible in selected patients with B-CLL: response-adjusted low-dose maintenance treatment with rituximab in patients with relapsed B-CLL, who achieved a partial or minimal response to prior rituximab therapy. Leuk Lymphoma 2007;48:905-11
   PubMed Web of Science ®Google Scholar
• Hodgson K, Ferrer G, Pereira A, Autoimmune cytopenia in chronic lymphocytic leukaemia: diagnosis and treatment. Br J Haematol 2011;154:14-22
   PubMed Web of Science ®Google Scholar
• Robak T. Monoclonal antibodies in the treatment of autoimmune cytopenias. Eur J Haematol 2004;72:79-88
   PubMed Web of Science ®Google Scholar
• Iannitto E, Ammatuna E, Marino C, Sustained response of refractory chronic lymphocytic leukemia in progression complicated by acute hemolitic anemia to anti-CD20 monoclonal antibody. Blood 2002;99:1096-7
   PubMed Web of Science ®Google Scholar
• Zaja F, Vianelli N, Sperotto A, Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. Leuk Lymphoma 2003;44:1951-5
   PubMed Web of Science ®Google Scholar
• Gupta N, Kuvaru S, Patel D, Rituximab based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia 2002;16:2092-5
   PubMed Web of Science ®Google Scholar
• Trape G, Fianchi L, Lai M, Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders. Haematologica 2003;88:223-5
   PubMed Web of Science ®Google Scholar
• Kaufman M, Limaye SA, Driscoll N, A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:892-9
   PubMed Web of Science ®Google Scholar
• Rossignol J, Michallet AS, Oberic L, Rituximab-cyclophosphamide-dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia. Leukemia 2011;25:473-8
   PubMed Web of Science ®Google Scholar
• Michallet AS, Rossignol J, Cazin B, Ysebaert L. Rituximab-cyclophosphamide-dexamethasone combination in management of autoimmune cytopenias associated with chronic lymphocytic leukemia. Leuk Lymphoma 2011;52:1401-3
   PubMed Web of Science ®Google Scholar
• Bowen DA, Call TG, Shanafelt TD, Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone. Leuk Lymphoma 2010;51:620-7
   PubMed Web of Science ®Google Scholar
• D'Arena G, Capalbo S, Laurenti L, Chronic lymphocytic leukemia-associated immune thrombocytopenia treated with rituximab: a retrospective study of 21 patients. Eur J Haematol 2010;85:502-7
   PubMed Web of Science ®Google Scholar
• Hegde UP, Wilson WH, White T, Cheson BD. Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood 2002;100:2260-2
   PubMed Web of Science ®Google Scholar
• Niitsu N, Hagiwara Y, Tanae K, Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy. J Clin Oncol 2010;28:5097-100
   PubMed Web of Science ®Google Scholar
• Ram R, Ben-Bassat I, Shpilberg O, The late adverse events of rituximab therapy – rare but there! Leuk Lymphoma. 2009;50:1083-95
   Google Scholar
• Hadjinicolaou AV, Nisar MK, Parfrey H, Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology (Oxford) 2011;50:2297-305
   PubMed Web of Science ®Google Scholar
• Wagner SA, Mehta AC, Laber DA. Rituximab-induced interstitial lung disease. Am J Hematol 2007;82:916-19
   PubMed Web of Science ®Google Scholar
• Heresi GA, Farver CF, Stoller JK. Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab: case report and review of the literature. Respiration 2008;76:449-53
   PubMed Web of Science ®Google Scholar
• Robak T, Robak P, Smolewski P. The evaluation and optimal use of rituximab in lymphoid malignancies. Blood Lymphat Cancer Targets Ther 2012;2:1-16
   Google Scholar
• Robak T, Robak E. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs 2011;25:13-25
   PubMed Web of Science ®Google Scholar